Knutson Keith L
University of Washington, Tumor Vaccine Group, Seattle 98195, USA.
Curr Opin Mol Ther. 2002 Aug;4(4):403-7.
DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated. DCVax-Brain is currently undergoing phase II clinical trials, and DCVax-Lung recently received approval from the US FDA for phase I clinical trials.
DCVax是一种基于树突状细胞的免疫疗法，是西北生物治疗公司正在开发的一种主动免疫平台，用于潜在治疗多种恶性肿瘤，包括激素难治性转移性前列腺癌、非小细胞肺癌、肾癌和多形性胶质母细胞瘤。DCVax平台通过使用纯化的肿瘤特异性抗原或在切除时从患者身上获取的肿瘤细胞提取物，针对特定癌症类型进行定制。DCVax - 前列腺的I/II期临床试验已经完成，III期临床试验最近已经启动。DCVax - 脑目前正在进行II期临床试验，DCVax - 肺最近获得美国食品药品监督管理局批准进行I期临床试验。
